TOH edition: Wednesday, 11 November 2026 · Health & Medicine
A year free of severe sickle cell pain crises: base-edited cells delivered that relief for patients in a trial
Reported by biospace.com
Publisher date:
Beam Therapeutics reports that its experimental cell therapy, risto-cel, helped patients with sickle cell disease go at least 12 consecutive months without severe pain crises, meeting its Phase 1/2 trial’s primary endpoint. The results were independently adjudicated, but the company has not disclosed the proportion who achieved that outcome or detailed safety data.
Sustained relief in trial patients shows that base editing could offer another path beyond recurring severe sickle cell pain crises, though treatment risks and longer-term outcomes remain important uncertainties.
Read the original report at biospace.com (opens in a new tab) →
Read the full front page of Wednesday, 11 November 2026 →
Get tomorrow's front page
Five reasons to believe in progress, delivered once a day.